Massachusetts' undeniable strength in life sciences has become a magnet for attracting world-class biomedical companies.  Collaboration catalyzes the translation of innovative discoveries into new technologies, diagnostics and ultimately patient treatments. MassBio's Annual Meeting focuses on the "Business of Science," showcasing the best science under collaboration between academia and industry - making Massachusetts the envy of the global life sciences cluster.

This one and one half day program includes:

• Fireside chats with Nobel Laureates and local biotech CEOs
• Expert panel discussions on the future of medicine
• Keynote address on the Impact of Human Genetics on Treating Complex Diseases
• Longwood Symphony performance
• Presentations on current work in cancer metabolism, diseases of aging, epigenetics, regenerative medicine and others
• Innovation 2010 Vendor Expo featuring best-in-class equipment providers
• Awards luncheon honoring the MassBio Innovator of the Year

Confirmed speakers include:

David Altshuler MD, PhD, Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT and Professor of Genetics and of Medicine, Harvard Medical School and Massachusetts General Hospital

Kees Been, President and Chief Executive Officer, EnVivo Pharmaceuticals, Inc.

Brian S. Bronk, Vice President of Chemistry, Satori Pharmaceuticals Inc.

David R. Cox, M.D., Ph.D., Senior Vice President and CSO, Applied Quantitative Genotherapeutics, Pfizer Inc.

Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium: The Takeda Oncology Company

Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer, Constellation Pharmaceuticals

Ole Isacson, Professor, M.D., Ph.D., Director of Center for Neuroregeneration Research, McLean Hospital/Harvard Medical School

David Mooney, PhD, Associate Dean for Chemical/Biological Sciences and Engineering, Harvard School of Engineering and Applied Sciences

James C. Mullen,  President and Chief Executive Officer, Biogen Idec

Brock Reeve, Executive Director, Harvard Stem Cell Institute

Richard Roberts, Ph.D., Chief Scientific Officer, New England Biolabs, Inc.

Lee Rubin, PhD, Director of Translational Medicine, Harvard Stem Cell Institute

Phillip A. Sharp, Ph.D., Institute Professor, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Juswinder Singh, PhD, Co-Founder and Chief Scientific Officer, Avila Therapeutics, Inc.

Henri Termeer, Chairman, President and CEO, Genzyme Corporation

Leonard Zon, M.D., Grousbeck Professor of Pediatrics, Harvard Medical School, and Director, Stem Cell Program, Children's Hospital Boston

The 2010 MassBio Annual Meeting will:

• Drive communication and collaboration to forge new business relationships between industry and academia

• Showcase the best science under collaboration between academia, biotech and pharma

• Educate up-and-coming investigators on the critical importance of collaboration to translate discovery into treatment

• Celebrate rising new scientific talent

Registration for the 2010 MassBio Annual Meeting includes access to all keynote presentations, panel discussions, breakfast, lunch, breaks, receptions and the Innovation 2010 Vendor Expo throughout the two days.

Price:
MassBio Member: $550 [On Site Registration: $600]
Non-Member: $650 [On Site Registration: $700]
Mass Bio Member (Academic, Nonprofit, Government): $350 [On Site Registration: $400]
Non-Member (Academic, Nonprofit, Government): $400 [On Site Registration $450]
Student (Need proper ID at registration on day of event): $99

Register